Mergers, acquisitions, and restructuring - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Mergers, acquisitions, and restructuring
A roundup of company moves and positioning from the pharmaceutical and biotechnology industries and contract service providers.

PTSM: Pharmaceutical Technology Sourcing and Management
Volume 3, Issue 9

London (Aug. 9)— Hikma Pharmaceuticals, a multinational pharmaceuticals group, agreed to acquire the entire issued share capital of Alkan Pharma, an Egyptian pharmaceuticals company, for a cash consideration of $60.5 million. The acquisition is scheduled to be completed in the second half of 2007, subject to meeting certain regulatory requirements. The acquisition will be funded entirely by debt.

New York (Aug. 8)American Oriental Bioengineering, a manufacturer and distributor of plant-based pharmaceutical and nutraceutical products, signed a legally binding letter of intent to acquire Guangxi Boke Pharmaceutical, a privately owned plant-based healthcare company, in a transaction valued at approximately $40.0 million.

Bad Vilbel, Germany (Aug. 3)Stada acquired the Russian pharmaceuticals group Makiz through a contract on the purchase of 100% of the shares of Zao Makiz-Pharma, Zao Skopinpharm and Zao Biodyne Pharmaceuticals. The contract was concluded by Stada's Russian subsidiary Nizhpharm Oao, Nizhny Novgorod. The staggered purchase price, which partly depends on the results of fiscal year 2007, is expected to amount to a total of approximately EUR 125 million ($172 million) less net debt of the group at closing, but will be EUR 135 million ($186 million) at maximum.

Los Angles, CA (Aug. 1)Abraxis BioScience, a biopharmaceutical company, acquired from Watson Pharmaceuticals a sterile injectable manufacturing facility located in Phoenix, Arizona. This facility, which has the ability to manufacture lyophilized powders, suspension products, and aqueous and oil solutions, currently manufactures products for Watson and other third parties.

South San Francisco, CA (Aug. 2)Genentech announced that the waiting period under the Hart-Scott-Rodino Act has expired and it has completed the acquisition of Tanox, Inc. Tanox shareholders approved the merger agreement on January 15, 2007.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here